NPI-001

Nacuity Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	NPI-001
Sponsor	Nacuity Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (PHASE1, PHASE2)
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome (PHASE3)
PK and PD Study of NPI-001 and Cysteamine Bitartrate (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NPI-001 CI brief — competitive landscape report
NPI-001 updates RSS · CI watch RSS
Nacuity Pharmaceuticals, Inc. portfolio CI